...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Concomitant antiplatelet and anticoagulation therapy: indications, controversies and practical advice.
【24h】

Concomitant antiplatelet and anticoagulation therapy: indications, controversies and practical advice.

机译:伴随抗血小板和抗凝治疗:适应症,争议和实用建议。

获取原文
获取原文并翻译 | 示例
           

摘要

The use of combination antiplatelet and anticoagulant therapy is commonly encountered in clinical practice and is often a source of clinical controversy in regards to the efficacy versus the safety of this regimen. The benefit of combination therapy relates to the probable additive effect of suppressing both platelet and coagulation factor activities. The risk of dual therapy is the potential for increased hemorrhagic events which may outweigh the clinical benefit. This review will focus on the clinical evidence that has demonstrated greater efficacy with combination therapy over either antiplatelet or anticoagulant therapy alone. Clinicians should consider the importance of documentation of combination therapy use in their patients in an effort to target those patients with the greatest benefit, and to avoid unnecessary complications.
机译:抗血小板和抗凝治疗相结合的使用在临床实践中很常见,并且在该方案的有效性与安全性之间经常引起临床争议。联合疗法的好处涉及抑制血小板和凝血因子活性的可能的累加作用。双重疗法的风险是出血事件增加的可能性,其可能超过临床收益。这篇综述将集中于已证明联合治疗比单独使用抗血小板或抗凝治疗具有更高疗效的临床证据。临床医生应考虑对患者进行联合治疗的文献记录的重要性,以针对那些获益最大的患者,并避免不必要的并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号